Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials
- 14 April 2023
- journal article
- review article
- Published by Elsevier in Leukemia Research
- Vol. 129, 107077
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AMLNew England Journal of Medicine, 2018
- Acute myelogenous leukemia in adolescents and young adultsPediatric Blood & Cancer, 2018
- Genomic Classification and Prognosis in Acute Myeloid LeukemiaNew England Journal of Medicine, 2016
- Acute Myeloid LeukemiaNew England Journal of Medicine, 2015
- Management of older or unfit patients with acute myeloid leukemiaLeukemia, 2014
- International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid LeukemiaJournal of Clinical Oncology, 2014
- Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic DifferentiationCancer Cell, 2010
- IDH mutations in glioma and acute myeloid leukemiaTrends in Molecular Medicine, 2010
- Utilization of the PICO framework to improve searching PubMed for clinical questionsBMC Medical Informatics and Decision Making, 2007
- Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older PatientsJournal of Clinical Oncology, 2007